"Bad" cholesterol levels are reduced by more than 50%!

On July 28, 2021, NewAmsterdam Pharma announced that, as an adjuvant therapy to statins, its oral investigational selective cholesteryl ester transfer protein (CETP) inhibitor obicetrapib has achieved positive top-line results in phase 2 clinical trials

Despite receiving the maximum tolerated dose of statin therapy, there are still more than 100 million people in the world who cannot meet the LDL-c target, which greatly increases their risk of heart attack, stroke and other adverse cardiovascular outcomes, so there is a high degree of unsatisfaction Medical needs

This randomized, double-blind, placebo-controlled, dose-escalating phase 2 clinical trial aims to evaluate the efficacy, safety and tolerability of obicetrapib as an adjuvant therapy for high-intensity statins

▲The molecular structure of Obicetrapib (picture source: Vaccinationist, Public domain, via Wikimedia Commons)

After the treatment period, the subjects continued to receive 4 weeks of safety follow-up and 15 weeks of pharmacokinetic (PK) follow-up

Note: The original text has been deleted

Reference materials:

[1] NewAmsterdam Pharma Reports Positive Results from Phase 2 Study of Oral Obicetrapib Demonstrating Over 50% LDL-Lowering as an Adjunct to High-Intensity Statins.